• Je něco špatně v tomto záznamu ?

Aflibercept Biosimilar MYL-1701P vs Reference Aflibercept in Diabetic Macular Edema: The INSIGHT Randomized Clinical Trial

SB. Bressler, A. Barve, PC. Ganapathi, K. Beckmann, RS. Apte, DM. Marcus, K. Baumane, S. Agarwal, P. Oleksy, DA. Reichstein, SS. Patel, J. Ernest, R. Dégi, V. Gupta, G. Kishino, M. Kamei, S. Loganathan, INSIGHT Study Group

. 2024 ; 142 (10) : 952-960. [pub] 20241001

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, randomizované kontrolované studie, multicentrická studie, srovnávací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25004007

IMPORTANCE: Biosimilars may be lower-cost alternatives to originator biologic products, potentially offering expanded access or reduced economic burden, but have not been evaluated with aflibercept in diabetic macular edema (DME). OBJECTIVE: To compare efficacy and safety of MYL-1701P, an aflibercept biosimilar, with reference aflibercept (Eylea [Regeneron]) in DME. DESIGN, SETTING, AND PARTICIPANTS: This was a double-masked, randomized clinical trial that included participants at 77 centers across the US, Europe, Japan, and India. Included in the analysis were individuals 18 years and older with type 1 or type 2 diabetes with central DME and best-corrected visual acuity (BCVA) letter score of 73 to 38 in the study eye using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart. Study data were analyzed from October to December 2021. INTERVENTIONS: Formulations of MYL-1701P (0.5-mg vial) or reference aflibercept every 4 weeks for 5 consecutive intravitreal injections, followed by every 8 weeks through week 52. MAIN OUTCOMES AND MEASURES: The primary outcome was the adjusted difference in least squares mean (SE) change from baseline BCVA letter score at week 8 with an equivalence margin of -3 to +3 letters. Secondary outcomes included change in central subfield thickness (CST), BCVA, number of injections over 52 weeks, incidence of adverse events (AEs), and antidrug antibodies (ADAs). RESULTS: A total of 355 participants (mean [SD] age, 62.2 [9.2] years; 216 male [60.8%]) were randomized to MYL-1701P (179 participants [50.4%]) and aflibercept (176 participants [49.6%]). At week 8, mean (SE) change in BCVA was 6.60 (0.55) letters vs 6.56 (0.55) letters in the MYL-1701P vs aflibercept groups. The adjusted mean difference of 0.04 letters (90% CI, -1.16 to 1.24 letters) met the primary outcome. At week 8, mean (SE) change in CST was -112 (7) μm vs -124 (7) μm in the MYL-1701P vs aflibercept groups (adjusted mean difference, 12 μm; 90% CI, -3 to 26 μm). The incidence of treatment-emergent AEs in the MYL-1701P and aflibercept arms were ocular (30.9% [55 of 178] vs 29.5% [52 of 176]), serious ocular (0.6% [1 of 178] vs 1.1% [2 of 176]), nonocular (65.2% [116 of 178] vs 65.3% [115 of 176]), and serious nonocular (16.9% [30 of 178] vs 11.9% [21 of 176]). The mean (SD) total number of injections was 8.4 (2.1) vs 8.7 (1.8) in the MYL-1701P vs aflibercept groups. The incidence of treatment-induced or treatment-boosted ADAs was 2.8% (5 of 177) vs 5.7% (10 of 176) in the MYL-1701P vs aflibercept arms. CONCLUSIONS AND RELEVANCE: MYL-1701P demonstrated clinical equivalence in regard to efficacy, with comparable safety and immunogenicity, to reference aflibercept. These findings support use of MLY-1701P as an alternative to reference aflibercept. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03610646.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25004007
003      
CZ-PrNML
005      
20250206105033.0
007      
ta
008      
250121s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1001/jamaophthalmol.2024.3458 $2 doi
035    __
$a (PubMed)39264599
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Bressler, Susan B $u Wilmer Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland
245    10
$a Aflibercept Biosimilar MYL-1701P vs Reference Aflibercept in Diabetic Macular Edema: The INSIGHT Randomized Clinical Trial / $c SB. Bressler, A. Barve, PC. Ganapathi, K. Beckmann, RS. Apte, DM. Marcus, K. Baumane, S. Agarwal, P. Oleksy, DA. Reichstein, SS. Patel, J. Ernest, R. Dégi, V. Gupta, G. Kishino, M. Kamei, S. Loganathan, INSIGHT Study Group
520    9_
$a IMPORTANCE: Biosimilars may be lower-cost alternatives to originator biologic products, potentially offering expanded access or reduced economic burden, but have not been evaluated with aflibercept in diabetic macular edema (DME). OBJECTIVE: To compare efficacy and safety of MYL-1701P, an aflibercept biosimilar, with reference aflibercept (Eylea [Regeneron]) in DME. DESIGN, SETTING, AND PARTICIPANTS: This was a double-masked, randomized clinical trial that included participants at 77 centers across the US, Europe, Japan, and India. Included in the analysis were individuals 18 years and older with type 1 or type 2 diabetes with central DME and best-corrected visual acuity (BCVA) letter score of 73 to 38 in the study eye using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart. Study data were analyzed from October to December 2021. INTERVENTIONS: Formulations of MYL-1701P (0.5-mg vial) or reference aflibercept every 4 weeks for 5 consecutive intravitreal injections, followed by every 8 weeks through week 52. MAIN OUTCOMES AND MEASURES: The primary outcome was the adjusted difference in least squares mean (SE) change from baseline BCVA letter score at week 8 with an equivalence margin of -3 to +3 letters. Secondary outcomes included change in central subfield thickness (CST), BCVA, number of injections over 52 weeks, incidence of adverse events (AEs), and antidrug antibodies (ADAs). RESULTS: A total of 355 participants (mean [SD] age, 62.2 [9.2] years; 216 male [60.8%]) were randomized to MYL-1701P (179 participants [50.4%]) and aflibercept (176 participants [49.6%]). At week 8, mean (SE) change in BCVA was 6.60 (0.55) letters vs 6.56 (0.55) letters in the MYL-1701P vs aflibercept groups. The adjusted mean difference of 0.04 letters (90% CI, -1.16 to 1.24 letters) met the primary outcome. At week 8, mean (SE) change in CST was -112 (7) μm vs -124 (7) μm in the MYL-1701P vs aflibercept groups (adjusted mean difference, 12 μm; 90% CI, -3 to 26 μm). The incidence of treatment-emergent AEs in the MYL-1701P and aflibercept arms were ocular (30.9% [55 of 178] vs 29.5% [52 of 176]), serious ocular (0.6% [1 of 178] vs 1.1% [2 of 176]), nonocular (65.2% [116 of 178] vs 65.3% [115 of 176]), and serious nonocular (16.9% [30 of 178] vs 11.9% [21 of 176]). The mean (SD) total number of injections was 8.4 (2.1) vs 8.7 (1.8) in the MYL-1701P vs aflibercept groups. The incidence of treatment-induced or treatment-boosted ADAs was 2.8% (5 of 177) vs 5.7% (10 of 176) in the MYL-1701P vs aflibercept arms. CONCLUSIONS AND RELEVANCE: MYL-1701P demonstrated clinical equivalence in regard to efficacy, with comparable safety and immunogenicity, to reference aflibercept. These findings support use of MLY-1701P as an alternative to reference aflibercept. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03610646.
650    _2
$a lidé $7 D006801
650    12
$a rekombinantní fúzní proteiny $x terapeutické užití $x aplikace a dávkování $7 D011993
650    12
$a receptory vaskulárního endoteliálního růstového faktoru $x aplikace a dávkování $7 D040262
650    12
$a diabetická retinopatie $x farmakoterapie $x diagnóza $x patofyziologie $7 D003930
650    12
$a makulární edém $x farmakoterapie $x patofyziologie $x diagnóza $7 D008269
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a ženské pohlaví $7 D005260
650    12
$a injekce intravitreální $7 D058449
650    12
$a zraková ostrost $x fyziologie $7 D014792
650    _2
$a lidé středního věku $7 D008875
650    12
$a inhibitory angiogeneze $x aplikace a dávkování $x terapeutické užití $x škodlivé účinky $7 D020533
650    12
$a biosimilární léčivé přípravky $x terapeutické užití $x škodlivé účinky $7 D059451
650    _2
$a výsledek terapie $7 D016896
650    _2
$a senioři $7 D000368
650    _2
$a vaskulární endoteliální růstový faktor A $x antagonisté a inhibitory $7 D042461
650    _2
$a optická koherentní tomografie $7 D041623
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a multicentrická studie $7 D016448
655    _2
$a srovnávací studie $7 D003160
700    1_
$a Barve, Abhijit $u Viatris Inc, Canonsburg, Pennsylvania
700    1_
$a Ganapathi, Prasanna C $u Viatris, Bangalore, India
700    1_
$a Beckmann, Katrin $u Viatris Healthcare GmbH, Hannover, Germany
700    1_
$a Apte, Rajendra S $u Washington University School of Medicine, St Louis, Missouri
700    1_
$a Marcus, Dennis M $u Southeast Retina Center Ophthalmology Department, Augusta, Georgia
700    1_
$a Baumane, Kristine $u Riga East Clinical University Hospital, Riga, Latvia
700    1_
$a Agarwal, Somesh $u M & J Institute of Ophthalmology-BJ Medical College, Gujarat, India
700    1_
$a Oleksy, Piotr $u Centrum Medyczne UNO-MED, Tarnow, Poland
700    1_
$a Reichstein, David A $u Tennessee Retina, Nashville
700    1_
$a Patel, Sunil S $u Retina Research Institute of Texas, Abilene
700    1_
$a Ernest, Jan $u Axon Clinical SRO, Praha 5-Smíchov, Czech Republic
700    1_
$a Dégi, Rozsa $u University of Szeged, Koranyi Favor 10-11, Szeged, Hungary
700    1_
$a Gupta, Vishali $u Postgraduate Institute of Medical Education & Research-Advanced Eye Centre, Punjab, India
700    1_
$a Kishino, Genichiro $u Kozawa Eye Hospital and Diabetes Center, Ibaraki, Japan
700    1_
$a Kamei, Motohiro $u Aichi Medical University Hospital, Aichi, Japan
700    1_
$a Loganathan, Subramanian $u Clinical Development & Medical Affairs Department, Biocon Biologics Ltd, Bangalore, Karnataka, India
710    2_
$a INSIGHT Study Group
773    0_
$w MED00180370 $t JAMA ophthalmology $x 2168-6173 $g Roč. 142, č. 10 (2024), s. 952-960
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39264599 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206105029 $b ABA008
999    __
$a ok $b bmc $g 2263633 $s 1240014
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 142 $c 10 $d 952-960 $e 20241001 $i 2168-6173 $m JAMA ophthalmology $n JAMA Ophthalmol $x MED00180370
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Možnosti archivace